LL-37 Peptide: The Human Cathelicidin, Antimicrobial and Wound-Healing Research, and Safety Questions

The LL-37 peptide is a 37-amino-acid antimicrobial peptide produced by the human body — the only member of the cathelicidin family of host-defense peptides found in humans. It is released by immune and epithelial cells as part of the first line of defense against bacteria, fungi, and viruses, and it also sends signals that shape inflammation and tissue repair. That combination has made LL-37 a subject of research in infection, chronic wounds, and inflammatory skin disease. It has also made it a compound with genuine safety questions, which is why its regulatory path has been uneven. This page covers what LL-37 is, what the research shows, why caution is warranted, and where it stands with the FDA.

What Is the LL-37 Peptide?

A Human Host-Defense Peptide

LL-37 is cleaved from a larger precursor protein called hCAP18 (human cationic antimicrobial protein, 18 kDa). The name describes the peptide itself: 37 amino acids, beginning with two leucines (L-L). It is produced by neutrophils, macrophages, and the epithelial cells lining the skin, airways, and gut — the surfaces where the body meets the outside world.

Antimicrobial Action

Like many antimicrobial peptides, LL-37 is positively charged and amphipathic, which allows it to interact with and disrupt the negatively charged membranes of many microbes. In laboratory studies it has shown activity against a broad range of bacteria, including some that form biofilms, as well as certain fungi and enveloped viruses. That broad-spectrum activity is one reason antimicrobial peptides are studied as a potential complement to conventional antibiotics.

Immune and Repair Signaling

LL-37 is not only a microbe-killer. It also acts as a signaling molecule: it can attract immune cells, influence cytokine release, affect how cells respond to microbial components, and promote processes involved in wound repair, including cell migration and new blood vessel formation. Whether it pushes inflammation up or down appears to depend heavily on context — the tissue, the concentration, and what else is present.

What the Research Shows

Chronic Wounds

Wound healing is the most clinically developed area of LL-37 research. Chronic wounds have been reported to show reduced levels of endogenous LL-37, and topical LL-37 has been studied in small human trials in hard-to-heal venous leg ulcers. Those studies are early-stage and small. They are a reason for continued research, not evidence of an established therapy.

Infection and Biofilms

Preclinical research has explored LL-37 and synthetic derivatives against resistant bacteria and biofilms. Much of the current drug-development interest focuses on engineered analogues designed to keep antimicrobial activity while reducing toxicity to human cells — an acknowledgment that the native peptide has limitations as a drug.

Inflammatory Skin Disease: Where LL-37 Cuts the Other Way

LL-37 is also implicated in the pathology of some conditions. Elevated or abnormally processed cathelicidin has been associated with rosacea and psoriasis, where it is thought to contribute to inflammation. This is a central point for anyone considering LL-37 as a therapy: more is not automatically better, and a peptide the body already regulates tightly can drive disease when that regulation fails.

How to Weigh the Evidence

Safety Questions

LL-37's safety picture is less settled than that of many peptides discussed in integrative practice, and our FDA peptide status tracker records that its earlier nomination was withdrawn over safety concerns.

• Tumor biology. Research on LL-37 in cancer is contradictory. In some tumor types it has been associated with growth-promoting (protumorigenic) effects; in others, with suppression. That uncertainty makes it a poor choice in patients with active or recent malignancy.
• Reproductive concerns. The tracker notes concerns raised regarding male reproduction as part of the earlier withdrawal.
• Inflammatory disease. Given its role in rosacea and psoriasis, LL-37 is a questionable choice in patients with those conditions.
• Cytotoxicity. At higher concentrations, membrane-active peptides can damage human cells as well as microbes — one reason developers pursue modified analogues.
• Immunogenicity and product quality. As with any injected peptide, aggregation and impurities raise immunogenicity questions. LL-37 has no established 503A pathway — its nomination was previously withdrawn and is only now re-scheduled for PCAC review — so there is no lawful compounded supply to point to; research-chemical products carry identity and purity risk.

LL-37 Dosing

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

There is no established human dose for LL-37 as a systemic therapy. The small human wound studies used topical application to the wound, which does not translate to injection. No existing Newtropin source establishes a dosing range, and we do not present one. Any use would be prescriber-determined, and given the open regulatory review, whether a compliant compounded preparation is available at all should be confirmed with the compounding partner first.

Regulatory Status

As of the tracker's July 2026 update, cathelicidin LL-37 is scheduled for a PCAC meeting before the end of February 2027, after previously sitting in a withdrawn state with no active review. The FDA's decision to reconsider it is a change in process, not a finding that it is safe or effective. Until that review concludes, its status for 503A compounding remains unsettled. Check the tracker for current status.

LL-37 is not an FDA-approved drug. Athletes subject to anti-doping rules should note that non-approved peptide substances fall within WADA's prohibited categories.

Where LL-37 Fits

LL-37 is usually discussed alongside the tissue-repair peptides on our peptides for healing hub, but its profile is different: stronger links to innate immunity, a longer list of safety questions, and less clinical history in integrative practice than BPC-157 or thymosin alpha-1. For skin-related repair, GHK-Cu has a longer and more consistent research record.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the LL-37 peptide?

LL-37 is a 37-amino-acid antimicrobial peptide made by the human body, cleaved from the precursor protein hCAP18. It is the only human cathelicidin and acts both as a direct antimicrobial and as an immune and repair signal.

What is LL-37 used for?

It has been researched for chronic wound healing, activity against resistant bacteria and biofilms, and immune modulation. The most clinically developed use is topical application in chronic wounds, studied in small early-stage trials. None of these is an FDA-approved indication.

Is LL-37 safe?

Its safety profile is not well established. Research on its role in tumors is contradictory, it is implicated in rosacea and psoriasis, and the FDA tracker records an earlier withdrawal over safety concerns including male reproduction. Caution is warranted, particularly in patients with a history of cancer or inflammatory skin disease.

What is the LL-37 dosage?

There is no established human dose for systemic LL-37. Published human studies used topical application to wounds. Any use is prescriber-determined.

Can LL-37 be compounded?

As of July 2026 it is scheduled for FDA PCAC review before the end of February 2027, after an earlier withdrawal. Its status for 503A compounding is unsettled until that review concludes; check the tracker and confirm with the compounding partner.